Vimarsana
Biggest News Aggregation in the World

Page 5 - Analyst Event News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Analyst Event. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Analyst Event Today - Breaking & Trending Today

Onto Innovation to Host Analyst Event and Participate in Upcoming Investor Events - Vimarsana News

Onto Innovation to Host Analyst Event and Participate in Upcoming Investor Events

Onto Innovation Inc. today invites registration for its Company sponsored analyst event on June 1, 2023 at the New York Stock Exchange, New York, New York. If you plan to attend in person, please... | May 11, 2023

ModernaTX, Inc: Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates - Vimarsana News

ModernaTX, Inc: Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates

First quarter 2023 revenues of $1.9 billion; GAAP net income of $79 million and GAAP diluted EPS of $0.19Company in negotiations for new orders for fall of 2023 in U.S., Japan, and EU, in addition to reiterating

Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023 - Vimarsana News

Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023

Company to share preliminary safety and efficacy data from ongoing Phase 1/2 trial of OCU400 for the treatment of retinitis pigmentosa and Leber congenital amaurosisMALVERN, Pa., April 11, 2023 --... | April 11, 2023

Moderna, Inc.: Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates - Vimarsana News

Moderna, Inc.: Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates

Fourth quarter 2022 revenues of $5.1 billion; GAAP net income of $1.5 billion and GAAP diluted EPS of $3.61Full-year 2022 revenues of $19.3 billion; GAAP net income of $8.4 billion and GAAP diluted EPS

Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 - Vimarsana News

Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701

16.02.2023 - - Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) observed and encouraging patient reported outcome data in all dose cohorts in ENPP1 Deficiency trial - - Rapid and significant increase in PPi observed in all dose cohorts ...